📊 RPRX Key Takeaways
Is Royalty Pharma plc (RPRX) a Good Investment?
Royalty Pharma demonstrates exceptional profitability (89.3% operating margin, 46.7% net margin) and fortress-like balance sheet with strong free cash flow generation ($718.2M). However, growth has stalled with only 5.1% revenue growth, flat net income YoY, and declining EPS of -6.8%, indicating shareholder dilution concerns and limited future value creation momentum.
Royalty Pharma plc Key Strengths (RPRX)
- Exceptional operating margins of 89.3% reflecting highly efficient royalty-based business model
- Strong free cash flow generation of $718.2M with 113.9% FCF margin indicating superior cash conversion
- Solid balance sheet with manageable debt-to-equity ratio of 0.90x and excellent interest coverage of 12.7x providing financial stability
RPRX Stock Risks: Royalty Pharma plc Investment Risks
- Severely slowing growth with only 5.1% revenue growth, 0% net income growth, and -6.8% EPS decline suggesting business maturation and shareholder dilution
- Low return on equity of 3% despite high profitability indicates capital structure inefficiency and poor returns on shareholder capital
- Inherent concentration risk in pharma royalty model dependent on existing pipeline and regulatory stability of underlying drugs
Key Metrics to Watch
- Revenue growth rate and pipeline of new royalty acquisitions to assess growth reacceleration
- Diluted EPS trajectory and share count changes to identify shareholder value destruction from issuance
- Free cash flow sustainability and capital allocation decisions (dividends, buybacks, debt reduction)
Royalty Pharma plc (RPRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 113.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.66x current ratio provides a solid financial cushion.
RPRX Profit Margin, ROE & Profitability Analysis
RPRX vs Healthcare Sector: How Royalty Pharma plc Compares
How Royalty Pharma plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Royalty Pharma plc Stock Overvalued? RPRX Valuation Analysis 2026
Based on fundamental analysis, Royalty Pharma plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Royalty Pharma plc Balance Sheet: RPRX Debt, Cash & Liquidity
RPRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Royalty Pharma plc's revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $2.53 reflects profitable operations.
RPRX Revenue Growth, EPS Growth & YoY Performance
RPRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $568.2M | $239.3M | $0.55 |
| Q3 2025 | $564.7M | $288.2M | $0.67 |
| Q2 2025 | $537.3M | $30.2M | $0.07 |
| Q1 2025 | $568.0M | $4.8M | $0.01 |
| Q3 2024 | $536.3M | $72.1M | $0.16 |
| Q2 2024 | $537.3M | $102.0M | $0.23 |
| Q1 2024 | $568.0M | $4.8M | $0.01 |
| Q3 2023 | $536.3M | $72.1M | $0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Royalty Pharma plc Dividends, Buybacks & Capital Allocation
RPRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Royalty Pharma plc (CIK: 0001802768)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RPRX
What is the AI rating for RPRX?
Royalty Pharma plc (RPRX) has an AI grade of B with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RPRX's key strengths?
Claude: Exceptional operating margins of 89.3% reflecting highly efficient royalty-based business model. Strong free cash flow generation of $718.2M with 113.9% FCF margin indicating superior cash conversion.
What are the risks of investing in RPRX?
Claude: Severely slowing growth with only 5.1% revenue growth, 0% net income growth, and -6.8% EPS decline suggesting business maturation and shareholder dilution. Low return on equity of 3% despite high profitability indicates capital structure inefficiency and poor returns on shareholder capital.
What is RPRX's revenue and growth?
Royalty Pharma plc reported revenue of $630.6M.
Does RPRX pay dividends?
Royalty Pharma plc pays dividends, with $104.5M distributed to shareholders in the trailing twelve months.
Where can I find RPRX SEC filings?
Official SEC filings for Royalty Pharma plc (CIK: 0001802768) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RPRX's EPS?
Royalty Pharma plc has a diluted EPS of $0.67.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RPRX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Royalty Pharma plc has a B grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RPRX stock overvalued or undervalued?
Valuation metrics for RPRX: ROE of 3.0% (sector avg: 15%), net margin of 46.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RPRX's AI grade for 2026?
Our dual AI analysis gives Royalty Pharma plc a combined B grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is RPRX's free cash flow?
Royalty Pharma plc's operating cash flow is $718.2M, with capital expenditures of N/A. FCF margin is 113.9%.
How does RPRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 46.7% (avg: 12%), ROE 3.0% (avg: 15%), current ratio 2.66 (avg: 2).